200,000+ products from a single source!
sales@angenechem.com
3562-84-3 | Benzbromarone
CAS No: 3562-84-3 Catalog No: AG003AX3 MDL No:MFCD00078962
Product Description
Catalog Number:
AG003AX3
Chemical Name:
Benzbromarone
CAS Number:
3562-84-3
Molecular Formula:
C17H12Br2O3
Molecular Weight:
424.0834
MDL Number:
MFCD00078962
IUPAC Name:
(3,5-dibromo-4-hydroxyphenyl)-(2-ethyl-1-benzofuran-3-yl)methanone
InChI:
InChI=1S/C17H12Br2O3/c1-2-13-15(10-5-3-4-6-14(10)22-13)16(20)9-7-11(18)17(21)12(19)8-9/h3-8,21H,2H2,1H3
InChI Key:
WHQCHUCQKNIQEC-UHFFFAOYSA-N
SMILES:
CCc1oc2c(c1C(=O)c1cc(Br)c(c(c1)Br)O)cccc2
EC Number:
222-630-7
UNII:
4POG0RL69O
Properties
Complexity:
405
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
423.913g/mol
Formal Charge:
0
Heavy Atom Count:
22
Hydrogen Bond Acceptor Count:
3
Hydrogen Bond Donor Count:
1
Isotope Atom Count:
0
Molecular Weight:
424.088g/mol
Monoisotopic Mass:
421.915g/mol
Rotatable Bond Count:
3
Topological Polar Surface Area:
50.4A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
5.7
Literature
| Title | Journal |
|---|---|
| Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. | Chemical research in toxicology 20170515 |
| Discriminating between adaptive and carcinogenic liver hypertrophy in rat studies using logistic ridge regression analysis of toxicogenomic data: The mode of action and predictive models. | Toxicology and applied pharmacology 20170301 |
| High content analysis assay for prediction of human hepatotoxicity in HepaRG and HepG2 cells. | Toxicology in vitro : an international journal published in association with BIBRA 20160601 |
| Multiparametric assay using HepaRG cells for predicting drug-induced liver injury. | Toxicology letters 20150702 |
| Hepatocellular toxicity of benzbromarone: effects on mitochondrial function and structure. | Toxicology 20141003 |
| A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. | Toxicological sciences : an official journal of the Society of Toxicology 20140101 |
| Structure-activity relationships of 44 halogenated compounds for iodotyrosine deiodinase-inhibitory activity. | Toxicology 20131206 |
| Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). | Toxicological sciences : an official journal of the Society of Toxicology 20131201 |
| A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. | Toxicological sciences : an official journal of the Society of Toxicology 20131101 |
| Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans. | Toxicological sciences : an official journal of the Society of Toxicology 20130301 |
| Identification of CYP isozymes involved in benzbromarone metabolism in human liver microsomes. | Biopharmaceutics & drug disposition 20121101 |
| Anti-inflammatory and immunomodulatory effects of iridoid glycosides from Paederia scandens (LOUR.) MERRILL (Rubiaceae) on uric acid nephropathy rats. | Life sciences 20121005 |
| In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. | Chemical research in toxicology 20120820 |
| Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. | Journal of medicinal chemistry 20120524 |
| [Stage-based treatment of integrative medicine on the quality of life in patients with gout]. | Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine 20120501 |
| Gout and organ transplantation. | Current rheumatology reports 20120401 |
| Relationship between serum allantoin and urate in healthy subjects and effects of benzbromarone in gout patients. | International journal of clinical pharmacology and therapeutics 20120401 |
| Computational prediction of metabolism: sites, products, SAR, P450 enzyme dynamics, and mechanisms. | Journal of chemical information and modeling 20120326 |
| Use of uric acid-lowering agents limits experimental cyclosporine nephropathy. | Nephron. Experimental nephrology 20120301 |
| A high throughput in vitro mrp2 assay to predict in vivo biliary excretion. | Xenobiotica; the fate of foreign compounds in biological systems 20120201 |
| Structure-based discovery of anti-influenza virus A compounds among medicines. | Biochimica et biophysica acta 20120201 |
| Corrector-mediated rescue of misprocessed CFTR mutants can be reduced by the P-glycoprotein drug pump. | Biochemical pharmacology 20120201 |
| Giant tophi in the calf. | Internal medicine (Tokyo, Japan) 20120101 |
| Can racial disparities in optimal gout treatment be reduced? Evidence from a randomized trial. | BMC medicine 20120101 |
| Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2. | PloS one 20120101 |
| The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age. | BMC geriatrics 20120101 |
| High plasma uric acid concentration: causes and consequences. | Diabetology & metabolic syndrome 20120101 |
| The EYA tyrosine phosphatase activity is pro-angiogenic and is inhibited by benzbromarone. | PloS one 20120101 |
| Benzofuran derivatives inhibit 11β-hydroxysteroid dehydrogenase type 1 activity in rat adipose tissue. | Biological & pharmaceutical bulletin 20120101 |
| Efficacy of benzbromarone in hyperuricemic patients associated with chronic kidney disease. | Nucleosides, nucleotides & nucleic acids 20111201 |
| Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). | PLoS computational biology 20111201 |
| [Drug-induced hepatic injury, the challenge for cause investigation]. | Rinsho byori. The Japanese journal of clinical pathology 20111201 |
| [Clinical strategies for prevention of drug-induced urinary calculi]. | Clinical calcium 20111001 |
| Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions. | Xenobiotica; the fate of foreign compounds in biological systems 20110901 |
| Impact of elevated uric acid on ventricular remodeling in infarcted rats with experimental hyperuricemia. | American journal of physiology. Heart and circulatory physiology 20110901 |
| [Assessment on the clinical efficacy and safety of xiezhuo chubi recipe in treating hyperuricemia]. | Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine 20110901 |
| The challenges of gout management in the elderly. | Drugs & aging 20110801 |
| [Gout - regardless of therapeutic options a 'forgotten' disease]. | Deutsche medizinische Wochenschrift (1946) 20110801 |
| Management of asymptomatic hyperuricaemia in patients with chronic kidney disease by Japanese nephrologists: a questionnaire survey. | Nephrology (Carlton, Vic.) 20110701 |
| Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites. | Drug metabolism and disposition: the biological fate of chemicals 20110701 |
| Identification and functional characterization of uric acid transporter Urat1 (Slc22a12) in rats. | Biochimica et biophysica acta 20110601 |
| Benzbromarone stabilizes ΔF508 CFTR at the cell surface. | Biochemistry 20110531 |
| Molecular docking studies and in vitro screening of new dihydropyridine derivatives as human MRP1 inhibitors. | Bioorganic & medicinal chemistry 20110515 |
| CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay. | Drug metabolism and disposition: the biological fate of chemicals 20110501 |
| Human urate transporter 1 (hURAT1) mediates the transport of orotate. | The journal of physiological sciences : JPS 20110501 |
| Developing potent human uric acid transporter 1 (hURAT1) inhibitors. | Journal of medicinal chemistry 20110428 |
| Impact of allopurinol use on urate concentration and cardiovascular outcome. | British journal of clinical pharmacology 20110401 |
| Serum CRP in patients with gout and effects of benzbromarone. | International journal of clinical pharmacology and therapeutics 20110301 |
| Interactions of urate transporter URAT1 in human kidney with uricosuric drugs. | Nephrology (Carlton, Vic.) 20110201 |
| Clinical images: Divergent patterns of joint remodeling following effective urate-lowering therapy in tophaceous gout. | Arthritis and rheumatism 20110101 |
| Hyperuricemia attenuates aortic nitric oxide generation, through inhibition of arginine transport, in rats. | Journal of vascular research 20110101 |
| MicroRNA expression patterns of the kidney in hyperuricemia mice treated with Xiezhuo Chubi Decoction. | Chinese journal of integrative medicine 20110101 |
| Tophaceous gout and renal insufficiency: a new solution for an old therapeutic dilemma. | Case reports in medicine 20110101 |
| Renal co-morbidity in patients with rheumatic diseases. | Arthritis research & therapy 20110101 |
| Clinical therapeutics in pregnancy. | Journal of biomedicine & biotechnology 20110101 |
| Genome-wide assessment of the carriers involved in the cellular uptake of drugs: a model system in yeast. | BMC biology 20110101 |
| Gout, genetics and ABC transporters. | F1000 biology reports 20110101 |
| Imaging in gout--what can we learn from MRI, CT, DECT and US? | Arthritis research & therapy 20110101 |
| Hyperuricemia is independently associated with coronary heart disease and renal dysfunction in patients with type 2 diabetes mellitus. | PloS one 20110101 |
| Quantitative estimation of urate transport in nephrons in relation to urinary excretion employing benzbromarone-loading urate clearance tests in cases of hyperuricemia. | Nephron extra 20110101 |
| Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. | Toxicological sciences : an official journal of the Society of Toxicology 20101201 |
| A predictive ligand-based Bayesian model for human drug-induced liver injury. | Drug metabolism and disposition: the biological fate of chemicals 20101201 |
| [Impact of serum uric acid level on the cardiovascular system as a risk factor]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20101201 |
| [Treatment of hyperuricemia and gout based on the guideline for the management of hyperuricemia and gout]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20101201 |
| Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. | Bioorganic & medicinal chemistry letters 20101101 |
| Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout. | Arthritis care & research 20100901 |
| The synthesis and characterization of cellular membrane affinity chromatography columns for the study of human multidrug resistant proteins MRP1, MRP2 and human breast cancer resistant protein BCRP using membranes obtained from Spodoptera frugiperda (Sf9) insect cells. | Talanta 20100615 |
| High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. | Diabetes care 20100601 |
| Letter by George regarding article, 'Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled cross-over preliminary study'. | Circulation. Heart failure 20100501 |
| High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells. | Drug metabolism and disposition: the biological fate of chemicals 20100401 |
| MRP transporters as membrane machinery in the bradykinin-inducible export of ATP. | Naunyn-Schmiedeberg's archives of pharmacology 20100401 |
| Biliary efflux transporters involved in the clearance of rosuvastatin in sandwich culture of primary rat hepatocytes. | Toxicology in vitro : an international journal published in association with BIBRA 20100301 |
| Risk factors of drug interaction between warfarin and nonsteroidal anti-inflammatory drugs in practical setting. | Journal of Korean medical science 20100301 |
| Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. | Circulation. Heart failure 20100101 |
| Serum cystatin C is a potential endogenous marker for the estimation of renal function in male gout patients with renal impairment. | Journal of Korean medical science 20100101 |
| Effect of fenofibrate on uric acid metabolism and urate transporter 1. | Internal medicine (Tokyo, Japan) 20100101 |
| Management of hyperuricemia in gout: focus on febuxostat. | Clinical interventions in aging 20100101 |
| Drug-induced eosinophilic pneumonia with pulmonary alveolar hemorrhage caused by benzbromarone. | Internal medicine (Tokyo, Japan) 20100101 |
| The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. | Arthritis research & therapy 20100101 |
| Effect of losartan and benzbromarone on the level of human urate transporter 1 mRNA. | Arzneimittel-Forschung 20100101 |
| [Human renal urate transpoter URAT1 mediates the transport of salicylate]. | Nihon Jinzo Gakkai shi 20100101 |
| High serum uric acid increases the risk for nonalcoholic Fatty liver disease: a prospective observational study. | PloS one 20100101 |
| Multidrug resistance protein transporter and Ins(1,4,5)P₃-sensitive Ca²+-signaling involved in adenosine triphosphate export via Gq protein-coupled NK₂-receptor stimulation with neurokinin A. | Journal of pharmacological sciences 20100101 |
| Advances in gout: some answers, more questions. | Arthritis research & therapy 20100101 |
| Benzbromarone pharmacokinetics and pharmacodynamics in different cytochrome P450 2C9 genotypes. | Drug metabolism and pharmacokinetics 20100101 |
| New advances in the treatment of gout: review of pegloticase. | Therapeutics and clinical risk management 20100101 |
| Epidemiology of gout. | Arthritis research & therapy 20100101 |
| Compliance in gout patients. | Acta reumatologica portuguesa 20100101 |
| Advances in the management of gout: critical appraisal of febuxostat in the control of hyperuricemia. | International journal of nephrology and renovascular disease 20100101 |
| New and improved strategies for the treatment of gout. | International journal of nephrology and renovascular disease 20100101 |
| Multiple testing for bioequivalence with pharmacokinetic data in 2 x 2 crossover designs. | Statistics in medicine 20091210 |
| [Effects of serial gout granules on insulin-resistance in primary gout patients]. | Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine 20091201 |
| Influence of luminal monosaccharides on secretion of glutathione conjugates from rat small intestine in vitro. | International journal of pharmaceutics 20091103 |
| Metabolomics in drug intolerance. | Current drug metabolism 20091101 |
| The role of transporters in the pharmacokinetics of orally administered drugs. | Pharmaceutical research 20090901 |
| Mouse GLUT9: evidences for a urate uniporter. | American journal of physiology. Renal physiology 20090901 |
| Gout--current diagnosis and treatment. | Deutsches Arzteblatt international 20090801 |
| Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. | Toxicology and applied pharmacology 20090615 |
| A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. | Annals of the rheumatic diseases 20090601 |
| Gout--what are the treatment options? | Expert opinion on pharmacotherapy 20090601 |
| Gene expression profiling in rat liver treated with various hepatotoxic-compounds inducing coagulopathy. | The Journal of toxicological sciences 20090601 |
| Structure-guided design, synthesis, and evaluation of salicylic acid-based inhibitors targeting a selectivity pocket in the active site of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1). | Journal of medicinal chemistry 20090528 |
| Effects of benzbromarone and allopurinol on adiponectin in vivo and in vitro. | Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20090401 |
| Characterization of a rat NADPH-dependent aldo-keto reductase (AKR1B13) induced by oxidative stress. | Chemico-biological interactions 20090316 |
| Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. | Annals of the rheumatic diseases 20090101 |
| Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. | Drug metabolism and disposition: the biological fate of chemicals 20090101 |
| Gout. Novel therapies for treatment of gout and hyperuricemia. | Arthritis research & therapy 20090101 |
| What lies behind serum urate concentration? Insights from genetic and genomic studies. | Genome medicine 20090101 |
| Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout. | Core evidence 20090101 |
| Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4. | British journal of pharmacology 20081201 |
| Febuxostat in the management of hyperuricemia and chronic gout: a review. | Therapeutics and clinical risk management 20081201 |
| Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. | American journal of hypertension 20081001 |
| SLC2A9 is a high-capacity urate transporter in humans. | PLoS medicine 20081001 |
| Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. | Annals of the rheumatic diseases 20080701 |
| Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). | Journal of medicinal chemistry 20080612 |
| [Stage-based treatment of gouty arthritis by combination therapy of traditional Chinese and Western medicines: a randomized controlled trial]. | Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine 20080601 |
| Modeling and synthesis of novel tight-binding inhibitors of cytochrome P450 2C9. | Bioorganic & medicinal chemistry 20080401 |
| [Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia]. | Nihon rinsho. Japanese journal of clinical medicine 20080401 |
| [Uricosuric agent]. | Nihon rinsho. Japanese journal of clinical medicine 20080401 |
| [New antihyperuricemic medicine: febuxostat, Puricase, etc]. | Nihon rinsho. Japanese journal of clinical medicine 20080401 |
| Modulation of sinusoidal and canalicular elimination of bilirubin-glucuronides by rifampicin and other cholestatic drugs in a sandwich culture of rat hepatocytes. | Hepatology research : the official journal of the Japan Society of Hepatology 20080301 |
| [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol]. | Nihon Jinzo Gakkai shi 20080101 |
| A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? | Drug safety 20080101 |
| Developments in the scientific and clinical understanding of gout. | Arthritis research & therapy 20080101 |
| Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: formation of glutathione adducts from a catechol intermediate. | Chemical research in toxicology 20071201 |
| Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein. | The Journal of biological chemistry 20071116 |
| Gene expression profiling of rat liver treated with serum triglyceride-decreasing compounds. | The Journal of toxicological sciences 20071001 |
| Excellent response to the clinical treatment of tophaceous gout. | Clinical rheumatology 20070901 |
| Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. | Clinical rheumatology 20070901 |
| Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. | Annals of the rheumatic diseases 20070801 |
| Morin (3,5,7,2',4'-pentahydroxyflavone) exhibits potent inhibitory actions on urate transport by the human urate anion transporter (hURAT1) expressed in human embryonic kidney cells. | Drug metabolism and disposition: the biological fate of chemicals 20070601 |
| Pseudotumor of gout in the patella of a kidney transplant recipient. | Nature clinical practice. Nephrology 20070601 |
| Block of CFTR-dependent chloride currents by inhibitors of multidrug resistance-associated proteins. | European journal of pharmacology 20070410 |
| Emerging therapies in the long-term management of hyperuricaemia and gout. | Internal medicine journal 20070401 |
| Human renal organic anion transporter 4 operates as an asymmetric urate transporter. | Journal of the American Society of Nephrology : JASN 20070201 |
| Flow cytometric monitoring of multidrug drug resistance protein 1 (MRP1/ABCC1) -mediated transport of 2',7'-bis-(3-carboxypropyl)-5-(and-6)- carboxyfluorescein (BCPCF) into human erythrocyte membrane inside-out vesicles. | Molecular membrane biology 20070101 |
| Activating effect of benzbromarone, a uricosuric drug, on peroxisome proliferator-activated receptors. | PPAR research 20070101 |
| Utilization of a one-dimensional score for surveying chemical-induced changes in expression levels of multiple biomarker gene sets using a large-scale toxicogenomics database. | The Journal of toxicological sciences 20061201 |
| Profiling of gene expression in rat liver and rat primary cultured hepatocytes treated with peroxisome proliferators. | The Journal of toxicological sciences 20061201 |
| Antihyperuricemic lignans from the leaves of Phyllanthus niruri. | Planta medica 20061101 |
| Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. | Arthritis and rheumatism 20061015 |
| EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). | Annals of the rheumatic diseases 20061001 |
| Amiodarone analog-dependent effects on CYP2C9-mediated metabolism and kinetic profiles. | Drug metabolism and disposition: the biological fate of chemicals 20061001 |
| [The inhibition of CYP2C9 isoenzyme in Cunninghamella blakesleeana AS 3. 910]. | Yao xue xue bao = Acta pharmaceutica Sinica 20061001 |
| Micellar electrokinetic capillary chromatographic method for the quantitative analysis of uricosuric and antigout drugs in pharmaceutical preparations. | Electrophoresis 20060601 |
| A convergent synthetic study of biologically active benzofuran derivatives. | Archives of pharmacal research 20060601 |
| Effect of fenofibrate in combination with urate lowering agents in patients with gout. | The Korean journal of internal medicine 20060601 |
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501 |
| Ciprofloxacin permeability and its active secretion through rat small intestine in vitro. | International journal of pharmaceutics 20060426 |
| A causal role for uric acid in fructose-induced metabolic syndrome. | American journal of physiology. Renal physiology 20060301 |
| The evaluation of some pharmaceutically acceptable excipients as permeation enhancers for amoxicillin. | International journal of pharmaceutics 20060203 |
| [Molecular mechanism in biological transport in the kidney: Urate transporter URAT1]. | Nihon rinsho. Japanese journal of clinical medicine 20060201 |
| A concise history of gout and hyperuricemia and their treatment. | Arthritis research & therapy 20060101 |
| Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. | Arthritis research & therapy 20060101 |
| Phenothiazine maleates stimulate MRP1 transport activity in human erythrocytes. | Biochimica et biophysica acta 20051230 |
| Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. | Drug metabolism and disposition: the biological fate of chemicals 20051201 |
| Sulfasalazine transport in in-vitro, ex-vivo and in-vivo absorption models: contribution of efflux carriers and their modulation by co-administration of synthetic nature-identical fruit extracts. | The Journal of pharmacy and pharmacology 20051201 |
| Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes. | Drug metabolism and disposition: the biological fate of chemicals 20051101 |
| [Clinical observation on electroacupuncture combined with medicine for treatment of acute gouty arthritis]. | Zhongguo zhen jiu = Chinese acupuncture & moxibustion 20051001 |
| CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant. | Molecular pharmacology 20050901 |
| Benzbromarone therapy in management of refractory gout. | The New Zealand medical journal 20050624 |
| Optimal management of chronic gout: attempting to render the (t)issues crystal-clear. | The New Zealand medical journal 20050624 |
| Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. | Hepatology (Baltimore, Md.) 20050401 |
| Inhibition of MRP1-mediated efflux in human erythrocytes by mono-anionic bile salts. | Anticancer research 20050101 |
| Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. | American journal of nephrology 20050101 |
| Gout in solid organ transplantation: a challenging clinical problem. | Drugs 20050101 |
| Charge and substituent effects on affinity and metabolism of benzbromarone-based CYP2C19 inhibitors. | Journal of medicinal chemistry 20041230 |
| Differential multidrug resistance-associated protein 1 through 6 isoform expression and function in human intestinal epithelial Caco-2 cells. | The Journal of pharmacology and experimental therapeutics 20041101 |
| Current management of gout in patients unresponsive or allergic to allopurinol. | Joint, bone, spine : revue du rhumatisme 20041101 |
| [Life-threatening adverse effects of pharmacologic antihyperuricemic therapy]. | Therapeutische Umschau. Revue therapeutique 20040901 |
| The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia. | Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20040901 |
| Spinal tophaceous gout mimicking a spinal tumor. | The Journal of rheumatology 20040701 |
| Quantitative binding models for CYP2C9 based on benzbromarone analogues. | Biochemistry 20040608 |
| Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). | Biochemical pharmacology 20040415 |
| Differential roles of Arg97, Asp293, and Arg108 in enzyme stability and substrate specificity of CYP2C9. | Molecular pharmacology 20040401 |
| D-glucose triggers multidrug resistance-associated protein (MRP)-mediated secretion of fluorescein across rat jejunum in vitro. | Pharmaceutical research 20040401 |
| Uric acid: role in cardiovascular disease and effects of losartan. | Current medical research and opinion 20040301 |
| Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. | The international journal of biochemistry & cell biology 20040201 |
| Function and localization of urate transporter 1 in mouse kidney. | Journal of the American Society of Nephrology : JASN 20040201 |
| Oxidized low-density lipoprotein autoantibodies in patients with primary gout: effect of urate-lowering therapy. | Clinica chimica acta; international journal of clinical chemistry 20040101 |
| Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. | Journal of the American Society of Nephrology : JASN 20040101 |
| Management of acute and chronic gouty arthritis: present state-of-the-art. | Drugs 20040101 |
| Benzbromarone withdrawn from the European market: another case of 'absence of evidence is evidence of absence'? | Clinical and experimental rheumatology 20040101 |
| Two male siblings with hereditary renal hypouricemia and exercise-induced ARF. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20031201 |
| [Chronic gout. Case report of a severe course of disease]. | Medizinische Klinik (Munich, Germany : 1983) 20031115 |
| Stopping progression in familial juvenile hyperuricemic nephropathy with benzbromarone? | Kidney international 20031101 |
| Multidrug resistance protein-6 (MRP6) in human dermal fibroblasts. Comparison between cells from normal subjects and from Pseudoxanthoma elasticum patients. | Matrix biology : journal of the International Society for Matrix Biology 20031101 |
| A new class of CYP2C9 inhibitors: probing 2C9 specificity with high-affinity benzbromarone derivatives. | Drug metabolism and disposition: the biological fate of chemicals 20030701 |
| Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. | Annals of the rheumatic diseases 20030601 |
| A case of exercise-induced acute renal failure in a patient with idiopathic renal hypouricemia developed during antihypertensive therapy with losartan and trichlormethiazide. | Hypertension research : official journal of the Japanese Society of Hypertension 20030601 |
| Effects of aspirin and/or salicylate on hydrolysis and glucuronidation of indomethacin in rat erythrocytes and hepatocytes. | Biological & pharmaceutical bulletin 20030501 |
| Selective and potent inhibitors of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone. | Chemico-biological interactions 20030201 |
| Urate transport via human PAH transporter hOAT1 and its gene structure. | Kidney international 20030101 |
| [Anti hyperuricemic agents]. | Nihon rinsho. Japanese journal of clinical medicine 20030101 |
| [Drug therapy for idiopathic hyperuricemia--introduction, dose, and side effects]. | Nihon rinsho. Japanese journal of clinical medicine 20030101 |
| [Essential hypertension]. | Nihon rinsho. Japanese journal of clinical medicine 20030101 |
| [Molecular mechanism for urinary excretion of hypoxanthine and xanthine]. | Nihon rinsho. Japanese journal of clinical medicine 20030101 |
| Flavonoids as inhibitors of MRP1-like efflux activity in human erythrocytes. A structure-activity relationship study. | Oncology research 20030101 |
| Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. | Arthritis and rheumatism 20020801 |
| Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients. | Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20020601 |
| Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6). | The Journal of biological chemistry 20020510 |
| Fulminant hepatic failure associated with benzbromarone treatment: a case report. | Journal of gastroenterology and hepatology 20020501 |
| [Summary of the Dutch College of General Practitioners' 'Gout' Standard]. | Nederlands tijdschrift voor geneeskunde 20020216 |
| [Hyperuricemia and gout--treatment]. | Deutsche medizinische Wochenschrift (1946) 20020201 |
| Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). | The Journal of biological chemistry 20011207 |
| [Vesical uric acid lithiasis in a child with renal hypouricemia]. | Anales espanoles de pediatria 20010901 |
| [A case of fulminant hepatitis, possibly caused by benzbromarone]. | Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20010401 |
| Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient. | Current rheumatology reports 20010201 |
| Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts. | Nephron 20001101 |
| Thoracic cord compression due to gout: a case report and literature review. | Journal of the Formosan Medical Association = Taiwan yi zhi 20000701 |
| Subjective sensation of heaviness in gout patients. | Hiroshima journal of medical sciences 20000601 |
| Fatal fulminant hepatic failure associated with benzbromarone. | Journal of hepatology 20000501 |
| Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone. | Clinical pharmacology and therapeutics 19991201 |
| Restoration of the uricosuric effect of probenecid after triglycylvasopressine administration in a gouty patient. | Clinical nephrology 19981001 |
| Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. | Annals of the rheumatic diseases 19980901 |
| Decreased serum concentrations of 1,25(OH)2-vitamin D3 in patients with gout. | Metabolism: clinical and experimental 19980301 |
| Effect of allopurinol and benzbromarone on the concentration of uridine in plasma. | Metabolism: clinical and experimental 19971201 |
| Expression of the multidrug resistance-associated protein (MRP) and chemoresistance of human non-small-cell lung cancer cells. | International journal of cancer 19970926 |
| Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cells. | International journal of cancer 19970328 |
| Renal handling of urate in a patient with familial juvenile gouty nephropathy. | Internal medicine (Tokyo, Japan) 19960701 |
| Biotransformation and uric acid lowering effect of benzbromarone in patients with liver cirrhosis - evidence for active benzbromarone metabolites? | European journal of medical research 19951016 |
| Severe hepatotoxicity related to benzarone: a report of three cases with two fatalities. | Liver 19950201 |
| Subfulminant hepatitis requiring liver transplantation after benzarone administration. | Journal of hepatology 19940601 |
| Hepatic injury caused by benzbromarone. | Journal of hepatology 19940301 |
| [The correction of hyperuricemia in patients with different forms of nephrolithiasis using allopurinol and Allomaron]. | Urologiia i nefrologiia 19940101 |
| Hyperuricemia in an infant with Taussig-Bing anomaly and interruption of the aortic arch. | Pediatric cardiology 19940101 |
| Renal hypouricemia due to enhanced tubular secretion of urate associated with urolithiasis: successful treatment of urolithiasis by alkalization of urine K+, Na(+)-citrate. | Nephron 19930101 |
| The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout. | European journal of clinical pharmacology 19930101 |
| [Long lasting normalization of uric acid after combination therapy with 300 mg allopurinol and 60 mg benzbromarone in patients with gout and hyperuricemia]. | Medizinische Klinik (Munich, Germany : 1983) 19920915 |
| Toxicological studies on a benzofurane derivative. I. A comparative study with phenobarbital on rat liver. | Toxicology and applied pharmacology 19901201 |
| [Effectiveness and tolerance of long-term uricosuric treatment]. | Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete 19901201 |
| Toxicological studies on a benzofurane derivative. II. Demonstration of peroxisome proliferation in rat liver. | Toxicology and applied pharmacology 19901201 |
| [Clinical studies on hyperuricemia and gout after transplantation]. | Hinyokika kiyo. Acta urologica Japonica 19900801 |
| [The effect of benzbromarone on hyperlipidemia in gout]. | Vutreshni bolesti 19900101 |
| [Drug-induced hepatitis due to benzarone (Fragivix): apropos of a clinical case report]. | Acta gastro-enterologica Belgica 19900101 |
| [Effects and side effects of benzbromaron in the initial treatment of hyperuricemia and gout. Results of a field study on 3899 patients]. | Fortschritte der Medizin 19780824 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.